.Pharmacolibrary.Drugs.ATC.L.L04AC16 .Pharmacolibrary.Drugs.ATC.L.L04AC16| name: | Guselkumab | |
| ATC code: | L04AC16 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 13.5 | L |
| clearance: | 0.516 | L/day |
| other parameters in model implementation | ||
Guselkumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. It is approved for the treatment of moderate-to-severe plaque psoriasis in adults and for psoriatic arthritis.
Pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis following subcutaneous administration. Population PK model from pooled clinical trials (brodalumab comparator group) with typical adult subject (mean body weight 90 kg).
Chen, Y, et al., & Sharma, A (2022). Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. Clinical and translational science 15(3) 749–760. DOI:10.1111/cts.13197 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34854241